Our Institutional Antibiogram; the Insight Gained in Selection of Empirical Antibiotics for the Treatment of Burn Wound Infection.
Main Article Content
Abstract
Objectives: The aim is to study the prevalence of bacteria involved in burn wound infection and the antibiotic susceptibility patterns of these bacteria.
Methodology: It was a cross-sectional, descriptive, observational study conducted in Burns and Plastic Surgery Center for six months. Sampling was done using a consecutive non-probability method for antibiogram construction. A summary of isolated bacteria's antibiotic susceptibilities to tested antibiotics and the prevalence of isolated species and genera of bacteria in percentages was determined by analyzing wound culture and susceptibility reports of burn wound clinical samples to construct an antibiogram.
Results: Collectively, the gram-negative bacilli (79.13%) and individually Klebsiella pneumonia (P.pneumonia) (23.33%), Pseudomonas aeruginosa (P.aeruginosa) (22.94%) and Staphylococcus aureus (S. Aureus) (14.55%) were most common respectively. The highest susceptibilities by all isolates were shown to carbapenems, piperacillin/tazobactam, and amikacin.
Conclusion: Gram-negative bacteria of Enterobacteriaceae family i.e. K.pneumoniae and Enterobacter spp. along with P.aeruginosa and gram-positive cocci were the most prevalent organisms isolated.
Article Details
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
Savage-Reid S, Moeng MS, Thomas T. Empirical antibiotic choice alters microbiological outcomes: Findings from comparative antibiograms in a trauma intensive care unit. South Afr J Crit Care 2020;36(2):96–103.
Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial antibiotic resistance: The most critical pathogens. Pathogens 2021;10(10):1310.
Urban-Chmiel R, Marek A, Stepien-Pysniak D, Wieczorek K, Dec M, Nowaczek A, et al. Antibiotic resistance in bacteria—A review. Antibiotics 2022;11(8):1079.
Uddin TM, Chakraborty AJ, Khusro A, Zidan BRM, Mitra S, Emran TB, et al. Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects. J Infect Public Health 2021;14(12):1750–66.
Ramey AM, Ahlstrom CA. Antibiotic-resistant bacteria in wildlife: Perspectives on trends, acquisition and dissemination, data gaps, and future directions. J Wildl Dis 2020;56(1):1–15.
Kaur I, Grover I, Singh J, Upveja K, Paul S. Analysis of microbial resistance and prescription preferences using antibiograms. J Infect Ther 2016;4(302):2332–0877.
Streicher LM. Exploring the future of infectious disease treatment in a post-antibiotic era: A comparative review of alternative therapeutics. J Glob Antimicrob Resist 2021;24:285–95.
Miethke M, Pieroni M, Weber T, Brönstrup M, Hammann P, Halby L, et al. Towards the sustainable discovery and development of new antibiotics. Nat Rev Chem 2021;5(10):726–49.
MacLean RC, San Millan A. The evolution of antibiotic resistance. Science 2019;365(6458):1082–3.
Sen Karaman D, Ercan UK, Bakay E, Topaloglu N, Rosenholm JM. Evolving technologies and strategies for combating antibacterial resistance in the advent of the postantibiotic era. Adv Funct Mater 2020;30(15):1908783.
Gilbert GL, Kerridge I. Hospital infection prevention and control (IPC) and antimicrobial stewardship (AMS): Dual strategies to reduce antibiotic resistance (ABR) in hospitals. Ethics Drug Resist Collect Responsib Glob Public Health 2020;89–108.
World Health Organization. Antimicrobial stewardship interventions: a practical guide. 2021; https://www.euro.who.int/en/publications/abstracts/antimicrobial-stewardship-interventions-a-practical-guide-2021.
Singhal T. “Rationalization of Empiric Antibiotic Therapy”–A Move Towards Preventing Emergence of Resistant Infections. Indian J Pediatr 2020;87(11):945–50.
Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, et al. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: A retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis 2021;21(2):241–51.
Cressman AM, MacFadden DR, Verma AA, Razak F, Daneman N. Empiric antibiotic treatment thresholds for serious bacterial infections: A scenario-based survey study. Clin Infect Dis 2019;69(6):930–7.
Corbin CK, Sung L, Chattopadhyay A, Noshad M, Chang A, Deresinksi S, et al. Personalized antibiograms for machine learning-driven antibiotic selection. Commun Med 2022;2(1):38.
Bassetti M, Rello J, Blasi F, Goossens H, Sotgiu G, Tavoschi L, et al. Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. Int J Antimicrob Agents 2020;56(6):106184.
Avershina E, Shapovalova V, Shipulin G. Fighting antibiotic resistance in hospital-acquired infections: Current state and emerging technologies in disease prevention, diagnostics, and therapy. Front Microbiol 2021;12:707330.
Corcione S, Lupia T, De Rosa FG. Microbiome in the setting of burn patients: Implications for infections and clinical outcomes. Burns Trauma 2020;8:tkaa033.
Gupta M, Naik AK, Singh SK. Bacteriological profile and antimicrobial resistance patterns of burn wound infections in a tertiary care hospital. Heliyon 2019;5(12).
Chaudhary NA, Munawar MD, Khan MT, Rehan K, Sadiq A, Bhatti HW, et al. Epidemiology, bacteriological profile, and antibiotic sensitivity pattern of burn wounds in the burn unit of a tertiary care hospital. Cureus 2019;11(6).
Tran C, Hargy J, Hess B, Pettengill MA. Estimated impact of low isolate numbers on the reliability of cumulative antibiogram data. Microbiol Spectr 2023;11(1):e03939-22.
Andrade FF, Silva D, Rodrigues A, Pina-Vaz C. Colistin update on its mechanism of action and resistance, present and future challenges. Microorganisms 2020;8(11):1716.
Liu P, Jiang Y, Jiao L, Luo Y, Wang X, Yang T. Strategies for the discovery of oxazolidinone antibacterial agents: Development and future perspectives. J Med Chem 2023;66(1):58–74.
Vidal L, Gafter-Gvili A, Borok S, Fraser A, Leibovici L, Paul M. Efficacy and safety of aminoglycoside monotherapy: Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2007;60(2):247–57.